Wedbush Maintains Underperform on Eikon Therapeutics, Lowers Price Target to $4

Benzinga · 1d ago
Wedbush analyst Robert Driscoll maintains Eikon Therapeutics (NASDAQ:EIKN) with a Underperform and lowers the price target from $5 to $4.